Aurora Cannabis
Market Cap
CA$2.3b
Last Updated
2020/12/03 00:47 UTC
Data Sources
Company Financials +
Executive Summary
Aurora Cannabis Inc. produces and distributes medical cannabis products worldwide. More Details
Rewards
Risk Analysis
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet and fair value.
Similar Companies
Share Price & News
How has Aurora Cannabis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ACB is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 29% a week.
Volatility Over Time: ACB's weekly volatility has increased from 21% to 29% over the past year.
Market Performance
7 Day Return
24.4%
ACB
6.2%
CA Pharmaceuticals
0.04%
CA Market
1 Year Return
-64.1%
ACB
29.3%
CA Pharmaceuticals
1.3%
CA Market
Return vs Industry: ACB underperformed the Canadian Pharmaceuticals industry which returned 18.9% over the past year.
Return vs Market: ACB underperformed the Canadian Market which returned 0.7% over the past year.
Shareholder returns
| ACB | Industry | Market | |
|---|---|---|---|
| 7 Day | 24.4% | 6.2% | 0.04% |
| 30 Day | 124.8% | 27.6% | 10.9% |
| 90 Day | 18.8% | 48.3% | 7.2% |
| 1 Year | -64.1%-64.1% | 29.3%29.3% | 5.0%1.3% |
| 3 Year | -82.6%-83.3% | -27.2%-28.2% | 13.5%2.4% |
| 5 Year | 84.1%77.4% | 274.2%271.5% | 54.2%30.5% |
Long-Term Price Volatility Vs. Market
How volatile is Aurora Cannabis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Aurora Cannabis Inc. (TSE:ACB) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$12.203 weeks ago | Simply Wall St
Are Investors Undervaluing Aurora Cannabis Inc. (TSE:ACB) By 46%?3 months ago | Simply Wall St
Aurora Cannabis'(TSE:ACB) Share Price Is Down 86% Over The Past Year.Valuation
Is Aurora Cannabis undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ACB (CA$14.05) is trading below our estimate of fair value (CA$30.24)
Significantly Below Fair Value: ACB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ACB is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: ACB is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ACB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACB is good value based on its PB Ratio (0.9x) compared to the CA Pharmaceuticals industry average (1.7x).
Next Steps
Future Growth
How is Aurora Cannabis forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
29.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACB's revenue (23.5% per year) is forecast to grow faster than the Canadian market (6.2% per year).
High Growth Revenue: ACB's revenue (23.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACB is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Aurora Cannabis performed over the past 5 years?
-89.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACB is currently unprofitable.
Growing Profit Margin: ACB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACB is unprofitable, and losses have increased over the past 5 years at a rate of 89.6% per year.
Accelerating Growth: Unable to compare ACB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-45%).
Return on Equity
High ROE: ACB has a negative Return on Equity (-158.72%), as it is currently unprofitable.
Next Steps
Financial Health
How is Aurora Cannabis's financial position?
Financial Position Analysis
Short Term Liabilities: ACB's short term assets (CA$430.7M) exceed its short term liabilities (CA$229.3M).
Long Term Liabilities: ACB's short term assets (CA$430.7M) exceed its long term liabilities (CA$374.0M).
Debt to Equity History and Analysis
Debt Level: ACB's debt to equity ratio (19.5%) is considered satisfactory.
Reducing Debt: ACB's debt to equity ratio has reduced from 297.6% to 19.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ACB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Aurora Cannabis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACB's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.0yrs
Average management tenure
CEO
Miguel Martin (48 yo)
0.25
Tenure
Mr. Miguel Martin serves as Chief Executive Officer and Director at Aurora Cannabis Inc. since September 8, 2020 and also was its Chief Commercial Officer since July 06, 2020. He serves as the President of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 4.08yrs | CA$2.86m | 0.0028% CA$ 64.4k | |
| Chief Financial Officer | 3.58yrs | CA$2.35m | 0.0015% CA$ 34.5k | |
| Chief Operating Officer | 3.58yrs | CA$1.78m | 0.0062% CA$ 142.5k | |
| Chief Legal Officer & Corporate Secretary | 2.92yrs | CA$1.66m | 0.0012% CA$ 27.6k | |
| CEO & Director | 0.25yr | no data | 0.017% CA$ 401.7k | |
| Executive Vice President of Information Services | 3.17yrs | no data | 0.00050% CA$ 11.6k | |
| Chief Science Officer | 2.08yrs | no data | 0.0083% CA$ 191.2k | |
| Vice President of Capital Markets & Investor Relations | no data | no data | no data | |
| Vice President of Communications & Public Relations | no data | no data | no data | |
| Executive Vice President | 1.67yrs | no data | no data | |
| Executive Vice-President of Human Resources | 3.5yrs | no data | 0.00013% CA$ 3.0k | |
| Chief Global Business Development Officer | 3.75yrs | CA$1.71m | no data |
3.0yrs
Average Tenure
51yo
Average Age
Experienced Management: ACB's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 4.08yrs | CA$2.86m | 0.0028% CA$ 64.4k | |
| CEO & Director | 0.25yr | no data | 0.017% CA$ 401.7k | |
| Independent Director | 1.83yrs | CA$322.74k | no data | |
| Independent Director | 0.83yr | CA$99.58k | no data | |
| Lead Independent Director | 1.83yrs | CA$332.74k | 0.0037% CA$ 85.3k | |
| Independent Director | 5.33yrs | CA$307.74k | 0.0044% CA$ 101.7k | |
| Independent Director | 0.83yr | CA$99.57k | no data | |
| Independent Director | 2.42yrs | CA$307.74k | 0.0016% CA$ 36.2k |
1.8yrs
Average Tenure
58yo
Average Age
Experienced Board: ACB's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 109.8%.
Top Shareholders
Company Information
Aurora Cannabis Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Aurora Cannabis Inc.
- Ticker: ACB
- Exchange: TSX
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$2.318b
- Shares outstanding: 183.66m
- Website: https://auroramj.com
Number of Employees
Location
- Aurora Cannabis Inc.
- Edmonton International Airport
- 4818 31 Street East
- Edmonton
- Alberta
- T9E 0V6
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 21P1 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Dec 2014 |
| ACB | NYSE (New York Stock Exchange) | Yes | Common Shares | US | USD | Dec 2014 |
| ACB | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Dec 2014 |
Biography
Aurora Cannabis Inc. produces and distributes medical cannabis products worldwide. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, including fa...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/12/03 00:47 |
| End of Day Share Price | 2020/12/02 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.